Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Blood (2024) 144 (5): 541–551.

https://doi.org/10.1182/blood.2023023625

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Blood (2023) 142 (Supplement 1): 323.

https://doi.org/10.1182/blood-2023-184703

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide, Tacrolimus or Cyclosporine a and Mycophenolate Mofetil Compared to Anti-Thymocyte Globulin tacrolimus or Cyclosporine a and Methotrexate Combinations As Graft- versus -Host Disease Prophylaxis Post Allogeneic Stem Cell Transplantation from Sibling and Unrelated Donors in Patients with Acute Myeloid Leukemia: a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2023) 142 (Supplement 1): 2181.

https://doi.org/10.1182/blood-2023-174821

Published: 2023

Journal Articles

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2023-181709

Published: 2023

Journal Articles

Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 657.

https://doi.org/10.1182/blood-2023-182823

Published: 2023

Journal Articles

Real-World Comparison of Venetoclax-Based Treatment Versus Intensive Chemotherapy As Bridging to Allogeneic Stem Cell Transplantation in MDS-IB2 Patients

Andrius Zucenka, Birutė Davainienė, Vilmantė Vaitekėnaitė, Rūta Čepulytė, Linas Davainis, Guoda Daukėlaitė, Lukas Kevličius, Regina Pileckytė, Igoris Trociukas, Laimonas Griškevičius

Blood (2023) 142 (Supplement 1): 6474.

https://doi.org/10.1182/blood-2023-178611

Published: 2023

Journal Articles

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Blood (2023) 141 (21): 2657–2661.

https://doi.org/10.1182/blood.2022019160

Published: 2023

Includes: Supplemental data

Journal Articles

10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG

Blood (2022) 140 (Supplement 1): 1281–1283.

https://doi.org/10.1182/blood-2022-166544

Published: 2022

Journal Articles

Pharmacokinetics and Immunogenicity of the First Doses of Peg-Asparaginase -an Alltogether Pilot Study

Merete Eybye Dam, Maddalena Centanni, Lena Friberg, Mats Karlsson, Line Stensig Lynggaard, Inga M. Johannsdottir, Hilde Skuterud Wik, Mats Heyman, Johan Malmros, Helene Hallböök, Goda Elizabeta Vaitkeviciene, Laimonas Griskevicius, Ólafur Gísli Jónsson, Ulrik Malthe Overgaard, Kjeld Schmiegelow, Birgitte Klug Albertsen

Blood (2022) 140 (Supplement 1): 8886–8887.

https://doi.org/10.1182/blood-2022-168655

Published: 2022

Journal Articles

Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021

Blood (2022) 140 (Supplement 1): 10434–10436.

https://doi.org/10.1182/blood-2022-169736

Published: 2022

Journal Articles

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Blood (2022) 140 (Supplement 1): 9125–9127.

https://doi.org/10.1182/blood-2022-157753

Published: 2022

Journal Articles

Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial

Peter Borchmann, Peter Vandenberghe, Alvaro Urbano-Ispizua, Corinne Haioun, Francois Lemonnier, Laimonas Griskevicius, Sébastien Maury, Silke Holtkamp, Birte Friedrichs, Gregor Zadoyan, Linda Hanssens, Toon Overstijns, Mario Assenmacher, Ulf Bethke, Iris Bürger, Olaf Reer, Ulrich Jaeger, Marie José Kersten

Blood (2022) 140 (Supplement 1): 12784–12785.

https://doi.org/10.1182/blood-2022-164650

Published: 2022

Journal Articles

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Jesse M. Tettero, Lok Lam Ngai, Costa Bachas, Dimitri A. Breems, Thomas Fischer, Bjørn Tore Gjertsen, Patrycja Gradowska, Laimonas Griskevicius, Jeroen J.W.M. Janssen, Gunnar Juliusson, Johan A. Maertens, Markus G Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Peter JM Valk, Bob Lowenberg, Gert J. Ossenkoppele, Jacqueline Cloos

Blood (2022) 140 (Supplement 1): 2027–2029.

https://doi.org/10.1182/blood-2022-157009

Published: 2022

Journal Articles

Venetoclax-Based Therapies for Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2 in Clinical Practice Setting

Andrius Žucenka, Lukas Kevličius, Linas Davainis, Birutė Davainienė, Kazimieras Maneikis, Regina Pileckytė, Dominika Vasilevska, Igoris Trociukas, Vilmantė Vaitekėnaitė, Laimonas Griškevičius

Blood (2022) 140 (Supplement 1): 3358–3359.

https://doi.org/10.1182/blood-2022-165459

Published: 2022

Journal Articles

Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT

Blood (2021) 138 (Supplement 1): 3954.

https://doi.org/10.1182/blood-2021-147684

Published: 2021

Journal Articles

A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party

Blood (2021) 138 (Supplement 1): 3937.

https://doi.org/10.1182/blood-2021-147001

Published: 2021

Journal Articles

Venetoclax, Actinomycin D and Low Dose Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia in Clinical Practice Setting

Andrius Zucenka, Vilmantė Vaitekėnaitė, Kazimieras Maneikis, Regina Pileckytė, Igoris Trociukas, Valdas Pečeliūnas, Laimonas Griškevičius

Blood (2021) 138 (Supplement 1): 3422.

https://doi.org/10.1182/blood-2021-144434

Published: 2021

Journal Articles

Upfront Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Idiopathic Aplastic Anemia: A Study on Behalf of the Saawp of EBMT

Audrey Françoise Petit, Dirk-Jan Eikema, Alexey Maschan, MD, Dalila Adjaoud, MD, Aleksander Kulagin, Alessandro Rambaldi, MD, Franca Fagioli, MD, Laimonas Griškevičius, MD PhD, John A Snowden, BSc (Hons), MBChB, MD FRCP, FRCPath, Jan-Erik Johansson, MD PhD, Jean-Hugues Dalle, MD PhD, Jenny Byrne, MD PhD, Antonio Risitano, Regis Peffault De Latour, MD PhD

Blood (2020) 136 (Supplement 1): 11–13.

https://doi.org/10.1182/blood-2020-136657

Published: 2020

Journal Articles

Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy

Jorge Sierra, MD, Pau Montesinos, MD PhD, Xavier Thomas, MD PhD, Laimonas Griškevičius, MD PhD, Thomas Cluzeau, MD PhD, Denis Caillot, Ollivier Legrand, MD, Clara Minotti, MD, Mario Luppi, Firas Farkas, MD, Bourras-Rezki Bengoudifa, MS, Geralyn Gilotti, MSc, Sejla Hodzic, MD, Alessandro Rambaldi, MD PhD, Adriano Venditti, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136083

Published: 2020

Journal Articles

Asparaginase-Associated Pancreatitis in ALL: Results from the NOPHO ALL2008 Treatment of Patients 1-45 Years

Blood (2019) 134 (Supplement_1): 3820.

https://doi.org/10.1182/blood-2019-122275

Published: 2019

NARROW

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party

Real-World Comparison of Venetoclax-Based Treatment Versus Intensive Chemotherapy As Bridging to Allogeneic Stem Cell Transplantation in MDS-IB2 Patients

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG

Pharmacokinetics and Immunogenicity of the First Doses of Peg-Asparaginase -an Alltogether Pilot Study

Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Venetoclax-Based Therapies for Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2 in Clinical Practice Setting

Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT

A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party

Venetoclax, Actinomycin D and Low Dose Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia in Clinical Practice Setting

Upfront Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Idiopathic Aplastic Anemia: A Study on Behalf of the Saawp of EBMT

Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy

Asparaginase-Associated Pancreatitis in ALL: Results from the NOPHO ALL2008 Treatment of Patients 1-45 Years

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only